Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01069120 · ClinicalTrials.gov registry record · Phase 3
Safety of 25 and 50 mg Proellex® in the Treatment of Women With Symptomatic Uterine Fibroids
A Phase 3 study, sponsored by Repros Therapeutics.
- Terminated
- Registry status
- Phase 3
- Development phase
- 27
- Enrollment target
NCT01069120 is a Phase 3 study that was terminated before completion, run by Repros Therapeutics. The registered enrollment target is 27 participants.
The verdict
NCT01069120, a Phase 3 study, was terminated before completion, sponsored by Repros Therapeutics.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 27 participants
- Enrollment target
Study Summary
Safety and efficacy study of 25 and 50 mg doses of Proellex
Interventions
- DRUG Proellex
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2009-04 |
| Est. Completion | 2009-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01069120
The ClinicalTrials.gov registry entry for NCT01069120 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Repros Therapeutics, which has 50 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Proellex is the first listed.
NCT01069120 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01069120 about?
NCT01069120 is a clinical study titled "Safety of 25 and 50 mg Proellex® in the Treatment of Women With Symptomatic Uterine Fibroids". Safety and efficacy study of 25 and 50 mg doses of Proellex
What is the current status of trial NCT01069120?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 27 participants. The study started on 2009-04. Estimated completion is 2009-08.
What interventions are being tested in trial NCT01069120?
The interventions under investigation include: Proellex (DRUG).
Who is sponsoring clinical trial NCT01069120?
This trial is sponsored by Repros Therapeutics, which has 50 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.